PASSAGE BIO, INC. Operating Lease, Liability, Current
PASSAGE BIO, INC. (PASG) had Operating Lease, Liability, Current of $1.15 million as of 2026-03-31, per its S-4 filed 2026-07-21.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-09-03
- 2026-03-31: Operating Lease, Liability, Current $1.15M.
- 2025-12-31: Operating Lease, Liability, Current $3.57M.
- 2025-09-30: Operating Lease, Liability, Current $3.54M.
- 2025-06-30: Operating Lease, Liability, Current $3.59M.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2026-03-31 | $1.15M S-4 · filed 2026-07-21 |
| 2025-12-31 | $3.57M S-4/A · filed 2026-09-03 |
| 2025-09-30 | $3.54M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $3.59M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $3.64M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $3.69M S-4/A · filed 2026-09-03 |
| 2024-09-30 | $3.73M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $3.70M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $3.67M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $3.37M 10-K · filed 2025-03-04 |
| 2023-09-30 | $3.35M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $3.33M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $3.30M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $3.27M 10-K · filed 2024-03-04 |
| 2022-09-30 | $3.25M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $3.23M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $3.12M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |